XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Læs mereEPS (adj.)
Udbytte %
Delårsrapport Q2'26
Delårsrapport Q3'26
Årsrapport '26
Gå ikke glip af noget - opret en konto og få alle de mulige fordele